The study of Alzheimer's biomarkers has led to an increased understanding of the multiple pathologies of the disease.  It has been proposed that AD and its' various stages can be defined by looking at biomarkers of amyloid, tau, and neurodegeneration (ATN).  The National Institute on Aging  (NIA) and the Alzheimer's Association (AA) are leading a workgroup on the development of a new research framework for Alzheimer's disease, as defined by ATN pathology.  

This Roundtable will allow experts in the field (academia, industry, and government) to provide perspectives on the new NIA-AA Research Framework and how it may be applied to clinical research. In addition, attendees will be able to give their feedback on the development of the NIA-AA Research Framework before the workgroup recommendations are finalized.